Search

Your search keyword '"Malloy, Stacy"' showing total 5 results
Start Over Author "Malloy, Stacy"
5 results on '"Malloy, Stacy"'

1. Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study

Author

Schlam, Ilana, Smith, D. Max, Peer, Cody, Sissung, Tristan, Schmidt, Keith T., Tan, Ming, Chitalia, Ami, Bishopric, Nanette H., Steinberg, Seth, Choo-Wosoba, Hyoyoung, Napoli, Giulia, Gallagher, Christopher, Ashai, Nadia, Whitaker, Kristen, Mainor, Candace, Tiwari, Shruti, Swanson, Nicole, Malloy, Stacy, Isaacs, Claudine, Figg, William Douglas, and Swain, Sandra M.

Published
2024
Full Text
View/download PDF

2. SurvivorCHIP: Evaluation of clonal hematopoiesis in women treated for breast cancer.

Author

Bahr, Reem, primary, Nosiri, Chidera, additional, Gui, Gege, additional, Mukherjee, Devdeep, additional, Hegde, Pranay, additional, Malloy, Stacy K, additional, Shastri, Preeti, additional, Peravali, Monica, additional, Chitalia, Ami, additional, Gallagher, Christopher, additional, DeStefano, Christin, additional, Dillon, Laura W., additional, Shenoy, Aarthi G., additional, and Hourigan, Christopher S., additional

Published
2024
Full Text
View/download PDF

3. Pharmacokinetics (PK) and pharmacogenomics (PGx) of ribociclib (ribo) in Black patients with metastatic breast cancer (mBC): The LEANORA study.

Author

Smith, Donald, primary, Schlam, Ilana, additional, Peer, Cody, additional, Sissung, Tristan, additional, Schmidt, Keith Thomas, additional, Tan, Ming Tony, additional, Chitalia, Ami, additional, Bishopric, Nanette H., additional, Steinberg, Seth M., additional, Choo-Wosoba, Hyoyoung, additional, Gallagher, Christopher, additional, Ashai, Nadia, additional, Whitaker, Kristen Danielle, additional, Mainor, Candace Bavette, additional, Tiwari, Shruti Rakesh, additional, Swanson, Nicole, additional, Malloy, Stacy K, additional, Isaacs, Claudine, additional, Figg, William Douglas, additional, and Swain, Sandra M., additional

Published
2024
Full Text
View/download PDF

5. Pharmacokinetics and Pharmacogenomics of Ribociclib in Black Patients with Metastatic Breast Cancer: The LEANORA study.

Author

Swain S, Schlam I, Smith DM, Peer C, Sissung T, Schmidt K, Tan M, Chitalia A, Bishopric N, Steinberg S, Choo-Wosoba H, Napoli G, Gallagher C, Ashai N, Whitaker K, Mainor C, Tiwari S, Swanson N, Malloy S, Isaacs C, and Figg W

Abstract

Underrepresented populations' participation in clinical trials remains limited, and the potential impact of genomic variants on drug metabolism remains elusive. This study aimed to assess the pharmacokinetics (PK) and pharmacogenomics (PGx) of ribociclib in self-identified Black women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer. LEANORA (NCT04657679) was a prospective, observational, multicenter cohort study involving 14 Black women. PK and PGx were evaluated using tandem mass spectrometry and PharmacoScan™ microarray (including CYP3A5*3 , *6 , and *7 ). CYP3A5 phenotypes varied among participants: 7 poor metabolizers (PM), 6 intermediate metabolizers (IM), and one normal metabolizer (NM). The area-under-the-curve did not significantly differ between PMs (39,230 hr*ng/mL) and IM/NMs (43,546 hr*ng/mL; p = 0.38). The incidence of adverse events (AEs) was also similar. We found no association between CYP3A5 genotype and ribociclib exposure. Continued efforts are needed to include diverse populations in clinical trials to ensure equitable treatment outcomes.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results